Important Information for Investors of Actinium Pharmaceuticals, Inc. (ATNM)
New York, April 9, 2025. Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (ATNM) between October 31, 2022, and August 2, 2024 (the “Class Period”), of the significant May 26, 2025 lead plaintiff deadline. The lawsuit alleges that Actinium Pharmaceuticals made materially false and misleading statements and/or failed to disclose material information during the Class Period, thereby violating the federal securities laws.
Background
Actinium Pharmaceuticals is a biopharmaceutical company engaged in the development of targeted therapies for various types of cancer. The company’s lead product candidate, I-131 Apalutamide Injection, is designed to treat prostate cancer.
Allegations
The complaint alleges that Actinium Pharmaceuticals made false and misleading statements and/or failed to disclose material information during the Class Period. Specifically, the complaint alleges that the company misrepresented the safety and efficacy of I-131 Apalutamide Injection, as well as the progress of its clinical trials. These misrepresentations allegedly led investors to purchase Actinium Pharmaceuticals securities at artificially inflated prices.
Lead Plaintiff Deadline
The lead plaintiff deadline is May 26, 2025. The lead plaintiff is the investor with the largest financial interest in the relief sought by the class. A lead plaintiff will act on behalf of all other class members in directing the litigation.
Effect on Individual Investors
If you purchased Actinium Pharmaceuticals securities during the Class Period, you may be eligible to recover your losses, as a result of Actinium Pharmaceuticals’ misrepresentations and/or failures to disclose material information. To determine if you are eligible for inclusion in the class, please contact Rosen Law Firm at [email protected] or call 212-614-5450.
Effect on the World
The securities fraud lawsuit against Actinium Pharmaceuticals is significant because it highlights the importance of transparency and honesty in the biopharmaceutical industry. The allegations of misrepresentations and failures to disclose material information have the potential to undermine investor confidence and harm the reputation of the company. This, in turn, could impact the entire biopharmaceutical sector and potentially discourage investment in promising new treatments and therapies.
Conclusion
The Rosen Law Firm encourages investors who purchased securities of Actinium Pharmaceuticals during the Class Period to contact the firm to discuss their potential legal rights. The firm represents investors worldwide, and it has a proven track record of recovering significant damages for its clients. The lead plaintiff deadline is May 26, 2025, so it is important for potential claimants to act quickly.
This lawsuit serves as a reminder that companies must be truthful and transparent with investors. Misrepresentations and failures to disclose material information can have serious consequences and negatively impact the entire industry. If you believe that you have been a victim of securities fraud, please do not hesitate to contact Rosen Law Firm to discuss your potential legal rights.
